Navigation Links
PremierEdge™ Stab Knives - 45°

ProductsPremierEdge™ Stab Knives - 45°
Company Oasis Medical
Item PremierEdge™ Stab Knives - 45°
Features 
Description PremierEdge™ Stab Knives - 45°.
Info Oasis Medical
Customer Service: (800) 528-9786
Web site: http://www.oasismedical.com

Related medicine products :

1. PremierEdge™ Stab Knives - 22.5°
2. PremierEdge™ Stab Knives - 30°
3. PremierEdge™ Clear Cornea Knives
4. PremierEdge™ Clear Cornea Knives - Parallel Sides
5. PremierEdge™ Clear Cornea Knives - Trapezoid
6. PremierEdge™ Tunnel Knives
7. PremierEdge™ Implant Knives
8. PremierEdge™ Slit Knives
9. PremierEdge™ Microsurgical Knife
10. PremierEdge™ MVR Knives
11. PremierEdge™ Stab Knives - 15°
Oscors proprietary quadripolar pacing wire design offers reliable and consistent pacing and sensing in the atrium and ventricle by combining two bipolar wires in one lead design. The wires for the at
The TME 227 T is a quadripolar pacing heartwire used for temporary cardiac pacing and monitoring during and after open-heart surgery. The TME 227 T features tines for fixation in the myocardium, whic
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially).
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially).
Medicine Products:
(Date:9/4/2008)... may be shortchanging their golden years by tappin...iversity of Illinois expert who has studied the fe..., More than three of every four Americans trim th...iming benefits early, a choice many might forego i... consequences, law professor Richard L. Kaplan say...
(Date:9/4/2008)...ncology contract research organization, has publis...uanced Approach to Get Into the Clinic Faster.&quo...al research scientist with 35 years of experience,...mmonly viewed as straightforward investigations ru...rue integration with preclinical, regulatory and c...
(Date:9/4/2008)...NORWICH, England and ONGAR, Ireland,Sept. 4 /PRNe...ofield Media,Europe Ltd, announced on the 29th Aug... publication from Silverdog Publishing., Health a... the iconic,Health and Safety at Work Act 1974 and.... It has been relied upon by blue-chip corporates,...
(Date:9/4/2008)...-FirstCall/ -- ULURU Inc. (Amex:,ULU) today announ...Weisel,Partners Healthcare Conference at 3:15 p.m....out ULURU Inc.:, ULURU Inc. is an emerging specia...ent of a portfolio of wound management, plastic su...nd consumers improved clinical,outcomes through co...
Breaking Medicine News(10 mins):Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3Health News:Schofield Publishing Enters the Newsletter Market 2
...ar fluid into the venous system, wearing a tight n...ing to a report published in the August issue of t...ngs indicate that wearing a tight necktie produces...re in patients with and without glaucoma. Although...
...d and neck cancer patients undergoing radiation ma... the University of Florida in Gainesville are clos...exercises work. Radiation therapy often causes pai...ring treatment but often find they cannot swallow ...
...’s bones and a new study reveals a good way to det...ne loss occurs after menopause, increasing chances...one size and strength. The Swedish study involved ...use. Every other year they had bone scans done to ...
...acteria has been cloned by scientists at The Scrip...associates with different "receptors" that detect .... Trif helps turn these detections of viruses and ... fight the invaders. The study, published in the J...
Other Medicine News:
(Date:9/3/2008)...Updates Zingo Launch Progress and Adlea ... Conference Call Today at 11:30 am ET, SOUTH SA.../ -- Anesiva,Inc. (Nasdaq: ANSV ) announced toda...focus on commercial and late-stage product develop...harmaceutical pain management,company. The company...
(Date:9/3/2008)...epeat-Dosing Study in Subjects with ALS, RICHMOND...o,BioSciences, Inc. (Nasdaq: SGMO ) announced tod...-509-801) to evaluate its drug, SB-509, in subject...on disease for which there,are limited treatment o...n injectable formulation of a plasmid,encoding a z...
(Date:9/2/2008)...e-FirstCall/ -- Forest Laboratories, Inc.,(NYSE: ...ced results from,two global Phase III studies of a...icholinergic for the treatment of patients with ch...h the ACCLAIM/COPD I&II,(AClidinium CLinical Trial...re COPD Patients) studies, once-daily aclidinium b...
(Date:9/2/2008)...ion, ONE to Build Hope and Give Help, MINNEAPOLIS...the,Republican Party Convention are sending a mess...world including evacuees in the Gulf Coast region,...g countries: "We are here,to help.", World Vision... to do,something unconventional. This event provid...
Breaking Medicine Technology:Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 2Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 3Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 5Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 2Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 3Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 4Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 5Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 6Senator Frist and Convention Delegates Support AIDS-Affected People Around the World, Raise Funds for Gustav Evacuees 2Senator Frist and Convention Delegates Support AIDS-Affected People Around the World, Raise Funds for Gustav Evacuees 3Senator Frist and Convention Delegates Support AIDS-Affected People Around the World, Raise Funds for Gustav Evacuees 4Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 378 1Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 378 2Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 378 3Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 378 4Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 378 5Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 378 6Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia 378 7DOV 21 947 Demonstrates Significant Body Weight and BMI Reductions in Drug Compliant Subjects in Phase Ib Clinical Study 374 1DOV 21 947 Demonstrates Significant Body Weight and BMI Reductions in Drug Compliant Subjects in Phase Ib Clinical Study 374 2DOV 21 947 Demonstrates Significant Body Weight and BMI Reductions in Drug Compliant Subjects in Phase Ib Clinical Study 374 3DOV 21 947 Demonstrates Significant Body Weight and BMI Reductions in Drug Compliant Subjects in Phase Ib Clinical Study 374 4DOV 21 947 Demonstrates Significant Body Weight and BMI Reductions in Drug Compliant Subjects in Phase Ib Clinical Study 374 5Radiologists identify early brain marker of Alzheimers disease 1953 1Radiologists identify early brain marker of Alzheimers disease 1953 2Radiologists identify early brain marker of Alzheimers disease 1953 3Cardiac Science Applauds Mass AED Training of Pittsburgh Educators 1951 1Cardiac Science Applauds Mass AED Training of Pittsburgh Educators 1951 2Cardiac Science Applauds Mass AED Training of Pittsburgh Educators 1951 3Cardiac Science Applauds Mass AED Training of Pittsburgh Educators 1951 4
...achieved both primary and secondary endpoints of,s...ed between,valopicitabine and ribavirin ~, CAMBRID... Idenix,Pharmaceuticals, Inc. today announced resu...ple combination therapy, consisting of,valopicitab...treatment of hepatitis C, pegylated interferon and...
....--(BUSINESS WIRE)--Jun 12, 2007 - Geron,Corporati...g,GRN163L, has demonstrated good pharmacokinetics...involving patients with chronic,lymphocytic leukem...n Colowick, M.D., M.P.H., the company,s president,...in Maui, Hawaii., Favorable Pharmacokinetics; Phar...
Other Medicine Technology:Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 2Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 3Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 4Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 5Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 6Geron's Telomerase Inhibitor Cancer Drug Demonstrates Good,Pharmacokinetics and Tolerability in Phase I/II Trial 2Geron's Telomerase Inhibitor Cancer Drug Demonstrates Good,Pharmacokinetics and Tolerability in Phase I/II Trial 3Geron's Telomerase Inhibitor Cancer Drug Demonstrates Good,Pharmacokinetics and Tolerability in Phase I/II Trial 4